Lyell CMO granted options for 47,500 shares
Lyell Immunopharma’s Chief Medical Officer received a 47,500-share stock option grant at a $12.20 exercise price with multi-year vesting.
Rhea-AI Filing Summary
Lyell Immunopharma, Inc. (LYEL) reported that its Chief Medical Officer, Jarrad Mattieu Aguirre, received a stock option grant for 47,500 shares of common stock on September 10, 2026. The option has an exercise price of $12.20 per share and expires on September 9, 2036. According to the vesting terms, 12.5% of the option shares will vest on February 28, 2027, with the remainder vesting in equal monthly installments over the following 42 months, subject to continued service.
After this award, Aguirre holds 20,279 shares of common stock directly, which include 14,451 restricted stock units that vest quarterly over a thirty-month period following July 9, 2026, also conditioned on continued service. No Rule 10b5-1 trading plan is reported for these transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 47,500 shares
Grant/Award
2 txns
Insider
Aguirre Jarrad Mattieu
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (right to buy) F2 | 47,500 | $0.00 | $0.00 |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 47,500 contracts (Direct);
Common Stock — 20,279 shares (Direct)
Footnotes (2)
- F1. Includes 14,451 restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan that are subject to time-based vesting and will be settled in common stock subject to vesting as follows: the RSUs vest quarterly over the thirty month period following July 9, 2026; in each case, subject to the reporting person providing service through the applicable vesting date.
- F2. 12.5% of the option shares will vest on February 28, 2027, with the remaining option shares to vest in equal monthly installments over the following 42 months, subject to the reporting person providing service through the applicable vesting date.
Key Figures
Option shares granted: 47,500 shares
Option exercise price: $12.20 per share
Option expiration date: September 9, 2036
+5 more
8 metrics
Option shares granted
47,500 shares
Stock option grant to Chief Medical Officer on September 10, 2026
Option exercise price
$12.20 per share
Exercise price for the 47,500-share stock option grant
Option expiration date
September 9, 2036
Expiration of the granted stock option
Initial cliff vesting
12.5% of option shares
Vests on February 28, 2027, subject to continued service
Remaining vesting period
42 months
Remaining option shares vest in equal monthly installments
Common shares held after transaction
20,279 shares
Total direct common stock holdings of Jarrad Aguirre after the filing
Restricted stock units included
14,451 RSUs
RSUs under the 2021 Equity Incentive Plan included in common share holdings
RSU vesting period
30 months
RSUs vest quarterly over thirty months following July 9, 2026
Key Terms
restricted stock units, 2021 Equity Incentive Plan, time-based vesting, stock option grant, +1 more
5 terms
restricted stock units financial
"Includes 14,451 restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2021 Equity Incentive Plan financial
"RSUs under the Issuer's 2021 Equity Incentive Plan that are subject to time-based vesting"
time-based vesting financial
"RSUs under the Issuer's 2021 Equity Incentive Plan that are subject to time-based vesting"
Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.
stock option grant financial
"12.5% of the option shares will vest on February 28, 2027"
Rule 10b5-1 regulatory
"No Rule 10b5-1 trading plan is reported for these transactions"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Lyell Immunopharma (LYEL) disclose for its Chief Medical Officer?
Lyell Immunopharma disclosed that Chief Medical Officer Jarrad Mattieu Aguirre received a stock option grant for 47,500 shares of common stock on September 10, 2026, at an exercise price of $12.20 per share, expiring on September 9, 2036, subject to a multi-year vesting schedule.
What are the vesting terms of the 14,451 RSUs reported for LYEL’s Chief Medical Officer?
The 14,451 RSUs reported are under Lyell Immunopharma’s 2021 Equity Incentive Plan and are subject to time-based vesting. The RSUs vest quarterly over a thirty-month period following July 9, 2026, and will be settled in common stock, subject to continued service through each vesting date.
Was the LYEL Form 4 transaction made under a Rule 10b5-1 trading plan?
The Form 4 indicates that no Rule 10b5-1 trading plan is reported for these transactions. The document-level checkbox for Rule 10b5-1 is explicitly unchecked.
What is the exercise price and expiration date of the new LYEL stock option grant?
The new stock option grant to Jarrad Aguirre has an exercise price of $12.20 per share and an expiration date of September 9, 2036, as disclosed in the Form 4 filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
